Technologies

Explore WARF Inventions and Patents

WARF Technologies

WARF’s portfolio of more than 1,900 technologies covers a wide range of categories, including analytical instrumentation, pharmaceuticals, food products, agriculture, research tools, medical devices, pluripotent stem cells, clean technology, information technology and semiconductors.

Information summaries, which describe each technology and its applications, benefits, inventors and patent status, can be downloaded, printed and shared by clicking on the technology category links to the left on this page.


Visit our subscription center to sign up for our monthly email updates and learn when new WARF technologies become available for licensing.
 

New Inventions

Production of Medium-Chain Fatty Acids from Biorefinery Residue

UW–Madison researchers led by Profs. Daniel Noguera and Timothy Donohue have developed a method for converting unreacted chemical components in stillage to valuable medium-chain fatty acids, such as hexanoic and octanoic acids, using a mixture of microbes (e.g., anaerobic microbiome).

Operationally, a portion of the stillage stream is separated and fed to a bioreactor containing the mixture of microbes, which transforms a fraction of the stillage to MCFAs. The other fraction of the stillage can be sent on to the anaerobic digester to generate electricity (similar to existing biorefineries).
P170271US04

New Hormone Analogs for Treating Hypoparathyroidism

UW–Madison researchers have developed backbone-modified analogs of PTH(1-34). The analogs exhibit advantageous properties; they are biased toward Gs activation/cAMP production relative to β arrestin recruitment.

The analogs were generated via an unconventional strategy in which the backbone of a natural PTHR-1 agonist was altered, rather than the side-chain complement. More specifically, selected α-amino acid residues were systemically replaced with either β-amino acid residues or with unnatural D-stereoisomer α-amino acid residues.

The researchers have shown that backbone-modification can rapidly identify potent agonists with divergent receptor-state selectivity patterns relative to a prototype peptide.
P180053US02

Enzymatic Depolymerization of Lignin

UW–Madison researchers provide the first demonstration of an in vitro enzymatic system that can recycle NAD+ and GSH while releasing aromatic monomers from natural and engineered lignin oligomers, as well as model compounds composed of similar chemical building blocks. Nearly 10 percent of beta-ether units were cleaved when the system was tested on actual lignin samples.

The relevant enzymes include dehydrogenases, β-etherases and glutathione lyases. In an exemplary version, the system uses the known LigD, LigN, LigE and LigF enzymes from Sphingobium sp. strain SYK-6. A newly discovered heterodimeric β-aryl etherase (BaeA) can be used in addition to or instead of LigE.
P170274US02

Soybeans with Increased Resistance to Sclerotinia Stem Rot and Drought Tolerance

UW–Madison researchers have demonstrated that knocking down expression of a specific soybean respiratory burst oxidase homolog protein (GmRBOH-VI) leads to enhanced resistance to S. sclerotiorum and confers drought tolerance.

Using protein sequence similarity searches, the researchers identified seventeen GmRBOHs and studied their contribution to Sclerotinia disease development, drought tolerance and nodulation. Transcript analysis of all seventeen GmRBOHs revealed that out of the six identified groups, group VI (GmRBOH-VI) was specifically and drastically induced following S. sclerotiorum challenge. Virus-induced gene silencing of GMRBOH-VI resulted in enhanced resistance to the fungus and, coincidently, drought stress.

Based on these discoveries, the researchers have developed modified soybeans and production methods available for licensing.
P170294US03

High Yield Method to Produce HMF from Fructose

UW–Madison researchers have discovered that a solvent system comprising water and a polar aprotic solvent (e.g., acetone) is ideally suited for converting C6 carbohydrates into HMF at reasonably low temperatures (such as 120°C), low acid concentration and at very high yields and efficiencies.

The C6 carbohydrate used in the method can be derived from any source including biomass (processed or unprocessed), cellulose and lignocellulosic sources, etc. The nature of the C6 carbohydrate is not critical to the method, although fructose is preferred.
P180329US01
View More

New Patents

Improved Manufacture of Porous Materials for Catalysis and More

A UW–Madison researcher has developed a new method for manufacturing porous metal-oxygen based materials. The method achieves structures with controlled porosity and shape based on air oxidation.

In brief, the materials are produced from metal alloys via an oxidative dealloying process that selectively removes one or more elements from the alloy and converts remaining elements into a stable metal-oxygen matrix having a controlled porosity. Once fabricated, the porous matrices are post-treated to render them suitable for various downstream applications.
P160073US01

Engineered Probiotics as Systemic Therapeutic Delivery Platform

UW–Madison researchers have developed bacteria engineered to systemically deliver a therapeutic polypeptide into a subject without the bacteria being substantially introduced into the bloodstream. This platform could be used to non-invasively increase systemic levels of hormones, peptides and potentially single-chain antibodies.

Using this new approach, the researchers engineered a lactic acid bacteria, Lactobacillus reuteri, to systemically deliver interleukin-22 (IL-22) in mice. The method is not limited to IL-22; other potential polypeptides include IL-35, insulin, leptin, a peptide inhibitor of PCSK9 and endolysin.
P160109US02

Inhibiting Metadherin/SND1 Interaction to Treat Cancer

UW–Madison researchers and collaborators have developed a method to fight tumor growth and metastasis using novel peptides that inhibit interaction between MTDH and a protein called SND1.

The researchers found that MTDH-SND1 protein interaction is important for the expansion and function of prostate tumors as well as luminal and basal breast tumor initiating cells. Their work provides novel peptides that target this protein complex to help control tumor initiation, recurrence and metastasis by combating tumor initiating cells, with minimal impact on normal tissues.
P140424US02
View More